Aerie Pharmaceuticals reported $1.63M in Interest Expense on Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Aerie Pharmaceuticals AERI:US $ 1.63M 5.89M
Alimera Sciences ALIM:US $ 1.36M 0M
Coherus Biosciences CHRS:US $ 8.97M 3.18M
Endo International Ordinary Shares ENDP:US $ 135.07M 8.53M
Insmed INSM:US $ 3.29M 8.06M
JAZZ PHA JAZZ:US $ 70.88M 17.81M
Merk MRK:US $ 243M 34M
Novartis NOVN:VX 201M 5M
Pacira Pharmaceuticals PCRX:US $ 10.25M 0.18M
Regeneron Pharmaceuticals REGN:US $ 13.6M 0.5M
Revance Therapeutics RVNC:US $ 1.93M 358K
Supernus Pharmaceuticals SUPN:US $ 1.16M 3.95M
Teva Pharmaceutical Industries TEVA:US $ 238M 58M
Valeant Pharmaceuticals VRX:CN $ 362M 16M
Zoetis ZTS:US $ 53M 1M